Inventor
GREENLEE WILLIAM
US29 patents
⚠️ This page may combine multiple inventors who share the name “GREENLEE WILLIAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACHILLION PHARMACEUTICALS INC
14 patentsUS11407738B2Aug 9, 2022
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC16 citations94
US11084800B2Aug 10, 2021
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
ACHILLION PHARMACEUTICALS INC18 citations94
US10919884B2Feb 16, 2021
Amide compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC20 citations94
US10906887B2Feb 2, 2021
Amino compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC20 citations94
US10662175B2May 26, 2020
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC20 citations94
US11708351B2Jul 25, 2023
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
ACHILLION PHARMACEUTICALS INC8 citations86
US11447465B2Sep 20, 2022
Pharmaceutical compounds for treatment of medical disorders
ACHILLION PHARMACEUTICALS INC16 citations86
US10807952B2Oct 20, 2020
Compounds for treatment of immune inflammatory disorders
ACHILLION PHARMACEUTICALS INC20 citations86
US12006307B2Jun 11, 2024
Pharmaceutical compounds for treatment of medical disorders
ACHILLION PHARMACEUTICALS INC3 citations75
US12162860B2Dec 10, 2024
Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
ACHILLION PHARMACEUTICALS INC2 citations73
US11649229B2May 16, 2023
Amide compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC3 citations73
US11649223B2May 16, 2023
Amino compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC3 citations73
US12338230B2Jun 24, 2025
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC0 citations63
US11926617B2Mar 12, 2024
Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
ACHILLION PHARMACEUTICALS INC0 citations63
UNIV CASE WESTERN RESERVE
6 patentsUS9789116B2Oct 17, 2017
Compositions and methods of modulating short-chain dehydrogenase activity
UNIV CASE WESTERN RESERVE16 citations82
US10869871B2Dec 22, 2020
Compositions and methods of modulating short-chain dehydrogenase activity
UNIV CASE WESTERN RESERVE5 citations68
US12391703B2Aug 19, 2025
Aldoketo reductase inhibitors and uses thereof
UNIV CASE WESTERN RESERVE1 citations61
US12098135B2Sep 24, 2024
Aldoketo reductase inhibitors and uses thereof
UNIV CASE WESTERN RESERVE1 citations59
US11518748B2Dec 6, 2022
Aldoketo reductase inhibitors and uses thereof
UNIV CASE WESTERN RESERVE1 citations59
US12479857B2Nov 25, 2025
Bax inhibitors and uses thereof
UNIV CASE WESTERN RESERVE0 citations49
NEUROGEN CORP
3 patentsUS6040448AMar 21, 2000
Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
NEUROGEN CORP10 citations71
US6384224B2May 7, 2002
Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands
NEUROGEN CORP3 citations60
US6331629B1Dec 18, 2001
Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands
NEUROGEN CORP3 citations60